文献速递消化道出血消化内镜

大型国际随机试验中Forrest IB(渗血)消化性溃疡出血再出血风险的重新评估

Reassessment of Rebleeding Risk of Forrest IB (Oozing) Peptic Ulcer Bleeding in a Large International Randomized Trial.
PubMed 文献 · Am J Gastroenterol · 2017-01-17

该研究为一项大型国际双盲试验(NCT00251979)的事后多变量分析,比较成功内镜止血后不同近期出血征象患者的早期再出血风险。安慰剂组中,Forrest IB(渗血)患者72小时再出血率为4.9%,显著低于其他高危征象;渗血患者使用埃索美拉唑与安慰剂再出血率相似。作者认为Forrest IB溃疡作为高危征象及推荐大剂量静脉质子泵抑制剂治疗的分类应予重新评估。

要点

  • 安慰剂组再出血率:喷射性出血22.5%、附着血凝块17.6%、非出血可见血管11.3%、渗血4.9%。
  • 与渗血相比,其他高危征象再出血风险显著更高,比值比从2.61至6.66。
  • 渗血患者72小时再出血率埃索美拉唑5.4%与安慰剂4.9%相似。

核心结论

  • 成功内镜止血后,Forrest IB渗血患者再出血率很低,与是否使用质子泵抑制剂或安慰剂无关。
  • 作者认为应将Forrest IB溃疡作为高危出血征象的分类及推荐大剂量静脉质子泵抑制剂治疗的建议予以重新评估。

研究设计与样本

  • 大型国际双盲随机试验(NCT00251979)的事后多变量分析,患者随机接受大剂量静脉埃索美拉唑或安慰剂治疗72小时。
  • 比较成功内镜止血后不同近期出血征象患者的再出血率,并比较质子泵抑制剂与安慰剂对再出血的影响。

主要发现

  • 安慰剂治疗72小时后,各征象再出血率:喷射性动脉出血22.5%、附着血凝块17.6%、非出血可见血管11.3%、渗血4.9%。
  • 与渗血患者相比,喷射性动脉出血、附着血凝块和非出血可见血管的再出血风险显著更高,比值比(95%CI)从非出血可见血管的2.61(1.05, 6.52)至喷射性动脉出血的6.66(2.19, 20.26)。
  • 渗血患者72小时再出血率埃索美拉唑组5.4%与安慰剂组4.9%相似。
  • 其他主要征象(喷射性动脉出血、非出血可见血管、附着血凝块)的再出血率质子泵抑制剂组低于安慰剂组,但治疗与征象的交互作用检验无统计学显著性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our aims were to assess risks of early rebleeding after successful endoscopic hemostasis for Forrest oozing (FIB) peptic ulcer bleeding (PUBs) compared with other stigmata of recent hemorrhage (SRH). METHODS: These were post hoc multivariable analyses of a large, international, double-blind study (NCT00251979) of patients randomized to high-dose intravenous (IV) esomeprazole (PPI) or placebo for 72 h. Rebleeding rates of patients with PUB SRH treated with either PPI or placebo after successful endoscopic hemostasis were also compared. RESULTS: For patients treated with placebo for 72 h after successful endoscopic hemostasis, rebleed rates by SRH were spurting arterial bleeding (FIA) 22.5%, adherent clot (FIIB) 17.6%, non-bleeding visible vessel (FIIA) 11.3%, and oozing bleeding (FIB) 4.9%. Compared with FIB patients, FIA, FIIB, and FIIA had significantly greater risks of rebleeding with odds ratios (95% CI's) from 2.61 (1.05, 6.52) for FIIA to 6.66 (2.19, 20.26) for FIA. After hemostasis, PUB rebleeding rates for FIB patients at 72 h were similar with esomeprazole (5.4%) and placebo (4.9%), whereas rebleed rates for all other major SRH (FIA, FIIA, FIIB) were lower for PPI than placebo, but the treatment by SRH interaction test was not statistically significant. CONCLUSIONS: After successful endoscopic hemostasis, FIB patients had very low PUB rebleeding rates irrespective of PPI or placebo treatment. This implies that after successful endoscopic hemostasis the prognostic classification of FIB ulcers as a high-risk SRH and the recommendation to treat these with high-dose IV PPI's should be re-evaluated.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Jensen DM, Eklund S, Persson T, et al. Reassessment of Rebleeding Risk of Forrest IB (Oozing) Peptic Ulcer Bleeding in a Large International Randomized Trial. Am J Gastroenterol. 2017. PMID: 28094314. doi:10.1038/ajg.2016.582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。